Avanos Medical, Inc. · NYSE:AVNS
Avanos Medical — Investor Presentation (January 2025)
17 slides from Avanos Medical's investor presentation, Jan 13, 2025
Slide 1: Michael Greiner, Interim CEO, January 13, 2025
Michael Greiner Interim CEO January 13, 2025
Slide 2: Forward-looking statements and non-GAAP disclosure
Certain matters in this presentation, including expectations and planning assumptions, any comments about our expected performance, and any estimates, projections, or statements relating to our business plans, objectives, acquisitions and transformation initiatives, constitute “forward-looking state
Slide 3: Two Differentiated Device Portfolios: Enteral Feeding and PM&R
TRIDENT*COOLIEF* TRIVISC* & GENVISC* Enteral Feeding ~$395M PM&R ~$290M Two Differentiated Device Portfolios: Enteral Feeding and Pain Management & Recovery (PM&R) Short-Term Feeding CORTRAK* 2 NEOMED* Pre-Surgical ON-Q* AMBIT* Post-Surgical GAME READY* Recovery MIC-KEY* Long-Term Feeding MARKET-LEA
Slide 4: Enteral Feeding market size and growth by therapy
Therapy/Trademark Market Size Market Growth Nasogastric Tube Placement & Short-Term Feeding (CORTRAK*/CORFLO*) Neonatal Feeding & Medication Delivery NEOMED*/ENFit® Enteral Feeding Portfolio Growth Outlook: At or Above Market † Market size is US-only $300M Initial Tube Placement & Long-Term Feeding
Slide 5: Enteral Feeding Near & Mid-Term Growth Catalysts
Near & Mid-Term Growth CatalystsNICU Feeding Enteral Feeding Near & Mid-Term Growth Catalysts Market Tailwinds • ENFit® transition addresses “never events" • Shift to guided-tube placement as standard • Rise in disease / patient-specific nutrition • Favorable global reimbursement Commercial Executio
Slide 6: Enteral Feeding Market Opportunity
$1B+ $2B $4B Market Opportunity Expanded Market Potential Market Enteral Feeding Market Opportunity Market Expansion with Future Technology Available Market with Execution Existing Opportunity
Slide 7: Our Vision: A Specialty Nutrition System
Our Vision: A Specialty Nutrition System Feeding tubes & sets Initial placement kits Accessories Pumps Specialized & disease-specific formula & supplements Extension & giving sets Current products Future products
Slide 8: Our Vision: Comprehensive Nutrition System for Newborns
Our Vision: Providing a Comprehensive Nutrition System for Newborns Milk collection bottles Breast pumps, accessories & lipid-saving technology Milk tracking & analysis system NG and percutaneous feeding tubes Gastric venting for CPAP belly Intelligent feeding Tube placement & confirmation Enteral s
Slide 9: Meet Carson!
Meet Carson!* *Individual experiences may vary, please consult with your physician.
Slide 10: PM&R market size and growth outlook
Radiofrequency Ablation (RFA) Solutions (ESENTEC*, Trident*, COOLIEF*) Hyaluronic Acid (Trivisc*/Genvisc*) PM&R Portfolio Growth Outlook: At Market Except HA † Market size is US-only $380M Catheter-Based Peripheral Nerve Block (ON-Q*/ambIT*) Cold & Compression (GAME READY*) $300M $320M † P r e - S u
Slide 11: PM&R Near & Mid-Term Growth Catalysts
Pre- Surgical PM&R Near & Mid-Term Growth Catalysts Post-Surgical & Recovery Near & Mid-Term Growth Catalysts Market Tailwinds • Aging, active population • Emphasis on non-opioid pain management • Procedural shift from hospital to ASC • U.S. NOPAIN Act reimbursement • Favorable international reimbur
Slide 12: PM&R Market Opportunity
Existing Opportunity $1.5B Available Market with Execution $2.5B Market Expansion with Future Technology $10B Served Market Size Expanded Market Potential Market PM&R Market Opportunity
Slide 13: Avanos Transformation Priorities: 2023–2025
Avanos Transformation Priorities: 2023–2025 Strategic & Commercial Optimization 1 Transform the Product Portfolio 2 Additional Cost Management Initiatives to Enhance Operating Profitability 3 Continued Efficient Capital Allocation Strategies to Expand Return on Invested Capital 4 DELIVERING VALUE TO
Slide 14: Avanos Transformation Progress: 2023-2024
• Enteral Feeding • Restructured North America sales organization to optimize standard of care initiatives • Launched 3 new products enhancing portfolio • Implemented go-direct initiatives in select European markets • PM&R • Restructured sales organization to focus on ASC opportunities • Launched Tr
Slide 15: Avanos Transformation Progress: 2023-2024 (continued)
• Maintained M&A discipline and conservative leverage level (exited 2024 <0.25x) • Continued share repurchases when market is dislocated vs our internal intrinsic value estimates ($25M current authorization) Avanos Transformation Progress: 2023-2024 Transform the Product Portfolio 3 Cost Management
Slide 16: Reaffirming Our Q4 2024 Guidance
Reaffirming Our Q4 2024 Guidance • Net Sales: $175M to $180M • Adjusted Gross Margin: ~59% • Adjusted SG&A: ~40% • Adjusted EPS: $0.38 to $0.43
Slide 17: Thank You
THANK YOU
Avanos Medical — Investor Presentation (January 2025) on 6ix